<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Vascular injury and atherothrombosis involve vessel infiltration by inflammatory leukocytes, migration of medial vascular smooth muscle cells to the intimal layer, and ultimately <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>A strategy to simultaneously target these pathological processes has yet to be identified </plain></SENT>
<SENT sid="2" pm="."><plain>The secreted protein, Slit2, and its transmembrane receptor, Robo-1, repel neuronal migration in the developing central <z:mp ids='MP_0008912'>nervous</z:mp> system </plain></SENT>
<SENT sid="3" pm="."><plain>More recently, it has been appreciated that Slit2 impairs chemotaxis of leukocytes and vascular smooth muscle cells toward diverse inflammatory attractants </plain></SENT>
<SENT sid="4" pm="."><plain>The effects of Slit2 on platelet function and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation have never been explored </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS AND RESULTS: We detected Robo-1 expression in human and murine platelets and megakaryocytes and confirmed its presence via immunofluorescence microscopy and flow cytometry </plain></SENT>
<SENT sid="6" pm="."><plain>In both static and shear microfluidic assays, Slit2 <z:hpo ids='HP_0008352'>impaired platelet adhesion</z:hpo> and spreading on diverse extracellular matrix substrates by suppressing activation of Akt </plain></SENT>
<SENT sid="7" pm="."><plain>Slit2 also prevented platelet activation on exposure to <z:chebi fb="13" ids="16761">ADP</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>In in vivo studies, Slit2 <z:hpo ids='HP_0003010'>prolonged bleeding times</z:hpo> in murine tail <z:mp ids='MP_0001914'>bleeding</z:mp> assays </plain></SENT>
<SENT sid="9" pm="."><plain>Using intravital microscopy, we found that after mesenteric arteriolar and carotid artery injury, Slit2 delayed vessel occlusion time and prevented the stable formation of occlusive arteriolar <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These data demonstrate that Slit2 is a powerful negative regulator of platelet function and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="11" pm="."><plain>The ability to simultaneously block multiple events in vascular injury may allow Slit2 to effectively prevent and treat thrombotic disorders such as <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>